Private financing · Biotech
Star Therapeutics raises $200m for its next drug pipeline
OrbiMed and Janus Henderson Investors co-lead the private financing.
Star Therapeutics announced a $200 million private financing on October 23, co-led by OrbiMed and Janus Henderson Investors. The capital will move preclinical programs into clinical development and support pipeline expansion.
The South San Francisco biotech is building its next set of therapies after Incyte acquired its Vega Therapeutics subsidiary in July. Other participants include Agent Capital, RA Capital Management, Sofinnova Investments and additional healthcare investors.
Use of funds
Advance preclinical programs into clinical development
Expand therapeutic pipeline
Funding history
Private financing · This round$200M